Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Etanercept in Rheumatoid Arthritis
NCT00357903Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 1997
- Primary completion
- Dec 2008
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 3 trial of etanercept in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), sponsored by Amgen. Started Apr 1997; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT00357903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00357903.